A case of hepatosplenic T-cell lymphoma successfully treated by HLA haploidentical stem cell transplantation
-
- Iwaki Noriko
- Department of Hematology, Toyama Red Cross Hospital, Toyama, Japan,
-
- Mochizuki Kanako
- Department of Hematology, Toyama Red Cross Hospital, Toyama, Japan,
-
- Ozaki Jun
- Department of Hematology, Toyama Red Cross Hospital, Toyama, Japan,
-
- Maeda Yoshinobu
- Division of Diagnostic Pathology, Toyama Red Cross Hospital, Toyama, Japan
-
- Kurokawa Toshiro
- Department of Hematology, Toyama Red Cross Hospital, Toyama, Japan,
Search this article
Abstract
<p>We report a case of hepatosplenic T-cell lymphoma (HSTL) transplanted from an HLA-haploidentical daughter. A 51-year-old man was referred due to liver function test abnormalities and fever. He was confirmed to have γδ-type HSTL by bone marrow and liver biopsies. He was treated with five cycles of a CHOP regimen. Although metabolic complete response (CR), as defined by positron emission tomography, was achieved, his bone marrow still contained tumor cells on polymerase chain reaction (PCR). He underwent transplantation using unmanipulated peripheral blood stem cells from his HLA-haploidentical daughter. The preconditioning regimen consisted of fludarabine, melphalan, busulfan and antithymocyte globulin. Graft-versus-host disease (GVHD) prophylaxis consisted of tacrolimus and short-term methotrexate. Neutrophil engraftment was achieved on day 14. His bone marrow exhibited a completely female phenotype by fluorescence in situ hybridization, and no lymphoma cells were detected by PCR on day 30. Although he developed grade II acute GVHD on day 47, it was successfully treated by prednisolone. He has a limited type of skin chronic GVHD and still receives oral immunosuppressive therapy. He remains in CR four years after transplantation.</p>
Journal
-
- Journal of Clinical and Experimental Hematopathology
-
Journal of Clinical and Experimental Hematopathology 60 (2), 55-59, 2020
The Japanese Society for Lymphoreticular Tissue Research
